Infusion 51a Joins the Overseas Conversation in the EMERGE GHI and PrecisionMed events in Dubai
Infusion 51a LP (“Infusion 51a” or the “Fund”), an impact investment fund investing in life-science companies aiming to help patients around the world, participated in the Dubai 2022 EMERGE GHI and PrecisionMed Expo, which took place May 24th-25th and are two of the most relevant events within the healthcare ecosystem in the MENA region. With […]
Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company’s Neuro-Oncology Medical Advisory Board
Walnut Creek, CA, USA, March 21, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director for Dana-Farber Cancer Institute, Center for Neuro-Oncology as a new member of its top-tier […]
Dr. Gerard Blobe, MD, PhD Joins Vivacitas Oncology’s Solid Tumor Medical Advisory Board
Walnut Creek, CA, USA, March 7th, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Gerard Blobe, MD, PhD has joined its Medical Advisory Board. Tina Runk, EVP of Clinical Operations and Director of the company, commented on Dr. Blobe’s addition to Vivacitas’ team: “We very much […]
Infusion 51a Sponsors the Champions for a Cure Tournament, an Event by To Cure a Rose Foundation
Pinehurst, North Carolina February 21st, 2022 – Infusion 51a LP (“Infusion 51a” or the “Fund”), an impact investment firm funding oncological companies to help millions of cancer patients to get better diagnosis and treatment options in unmet solid tumors, sponsored on February 20th and 21st at the Champions for a Cure Tournament, a golf event […]